Previous 10 | Next 10 |
home / stock / kaltf / kaltf news
SAN FRANCISCO and TEL AVIV, Israel, July 29, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “ Company ” or “ Kalytera ”) announced today that shareholder votes on the election of directors, the approval of the Compan...
SAN FRANCISCO and TEL AVIV, Israel, July 26, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “ Company ” or “ Kalytera ”) announced today that after consultations with major shareholders, the board of directors of the...
The legalization of medicinal and recreational cannabis, as well as the increasing popularity of Cannabidiol, or CBD, for the treatment of various ailments, has been a major boom period for investors in the cannabis sector. But it hasn't been all pots of gold at the end of the rainbow. Kalyter...
SAN FRANCISCO and TEL AVIV, Israel, July 16, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that it has completed Study KAL-07, the Food Effect and QTc Study, that is part of the Company’s pro...
SAN FRANCISCO and TEL AVIV, Israel, July 05, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “ Company ” or “ Kalytera ”) announced today that it is holding its annual and special meeting of shareholders on July 29, 2...
Quick Take Kalytera Therapeutics ( KALTF ) announced it has agreed to acquire a majority interest in Oregon 01 for $3.5 million. Oregon 01 is doing business as ‘Clean Bi Design’ and will operate a hemp-based CBD extraction facility in Amity, Oregon. Kalytera is developing...
Kalytera Therapeutics ( OTCQB:KALTF +5.7% ) has signed a Letter of Intent to acquire a majority interest in Oregon 01, LLC (doing business as “Clean Bi Design”), which will operate a hemp-based cannabidiol extraction facility in Amity, Oregon. More news on: Kalytera Thera...
Business Will Be Amongst Largest Such Operations in U.S. Transaction Will Provide Near-Term Path to Revenues SAN FRANCISCO and TEL AVIV, Israel, June 27, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “ Company ” ...
SAN FRANCISCO AND TEL AVIV, Israel, June 25, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today provided an update on its lead product development program evaluating cannabidiol (“ CBD ”) for the pre...
SAN FRANCISCO and TEL AVIV, Israel, June 21, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that it has granted stock options on June 19, 2019 to the directors of the Company. The stock option...
News, Short Squeeze, Breakout and More Instantly...
Kalytera Therapeutics Company Name:
KALTF Stock Symbol:
OTCMKTS Market:
Kalytera Therapeutics Website:
SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has received comments from the Australian Human Research Ethics Committee (the “...
SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that the Australian Human Research Ethics Committee (HREC) will meet on February 16 th to...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today announced revised, improved pricing for the initial tranche of funds that the Co...